Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $794.70

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been given a consensus recommendation of “Moderate Buy” by the twenty-seven brokerages that are covering the company, MarketBeat reports. Eight equities research analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $784.7727.

REGN has been the topic of several recent analyst reports. Evercore ISI boosted their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Truist Financial boosted their price objective on Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Finally, BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Dodge & Cox increased its position in Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after buying an additional 1,502,198 shares in the last quarter. Norges Bank acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $628,151,000. AQR Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 528.7% during the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock valued at $405,596,000 after acquiring an additional 606,612 shares in the last quarter. Invesco Ltd. raised its position in shares of Regeneron Pharmaceuticals by 38.0% during the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after purchasing an additional 408,649 shares during the period. Finally, Acadian Asset Management LLC raised its position in shares of Regeneron Pharmaceuticals by 234.7% during the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock worth $244,480,000 after purchasing an additional 326,583 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $749.44 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company has a 50 day simple moving average of $758.68 and a two-hundred day simple moving average of $648.66. The company has a market capitalization of $78.77 billion, a PE ratio of 17.95, a P/E/G ratio of 1.96 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same period in the prior year, the firm posted $12.46 EPS. The company’s quarterly revenue was up .9% on a year-over-year basis. Research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.